Literature DB >> 12954135

Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism.

Helene Jönsson1, Sören Mattsson.   

Abstract

One or several radioiodine uptake measurements are usually made to calculate the activity necessary to give the prescribed absorbed dose to the thyroid of patients treated for hyperthyroidism. If the initial uptake, estimated at time zero, and the effective half-time are to be determined, more than one uptake measurement is needed. The first measurement is often made 24 h after administration of radioiodine. In this work we show that one uptake measurement taken at an appropriate time postadministration is sufficient to determine the product of the initial uptake and the effective half-time, and thus give an estimate of the absorbed dose. A total of 515 patients (14-92 years) who received radioiodine treatment for hyperthyroidism at Malmö University Hospital were analyzed. Individual effective half-times were determined from three uptake measurements, 24 h, 48 h, and a third measurement between 3 and 8 days after the intake of the test activity and were used for the absorbed dose calculations. We found a significant linear relationship between the uptake at 4 days or longer after administration and the product of initial uptake and effective half-time. The relationship was independent on diagnosis, age, and sex of the patient. Therefore a single uptake measurement is sufficient for an accurate absorbed dose determination, provided that the measurement is made at least 4 days after administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954135     DOI: 10.1089/108497803322285233

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  5 in total

1.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.

Authors:  Heribert Hänscheid; Cristina Canzi; Wolfgang Eschner; Glenn Flux; Markus Luster; Lidia Strigari; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-11       Impact factor: 9.236

2.  Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases.

Authors:  Martin Andersson; Sören Mattsson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

3.  The route of administration (oral vs intravenous) does not influence dose or outcome in Graves' disease and unifocal autonomy.

Authors:  Peter Schneider; Johannes Biko; Heribert Hänscheid; Stephan Hilliger; Christos Koutsampelas; Michael Kranzfelder; Stephan Ladner; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-10       Impact factor: 9.236

4.  Radioiodine treatment outcome by dosimetric parameters and renal function in hyperthyroidism.

Authors:  Joachim N Nilsson; Rebecca Elovsson; Daniel Thor; Jan Calissendorff; Oscar Ardenfors
Journal:  Thyroid Res       Date:  2022-04-25

5.  Gender differences in estimating I-131 thyroid uptake from Tc-99m thyroid uptake for benign thyroid disease.

Authors:  Amna Al-Jabri; Jennie Cooke; Seán Cournane; Marie-Louise Healy
Journal:  Br J Radiol       Date:  2020-12-11       Impact factor: 3.039

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.